RxDoctor Payments Data

Kara Guinta, NP

Nurse Practitioner · Perrysburg, OHNPI 1104487594

Payments from drug & device makers

$1,670in general payments, 2019–2025

Across 97 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$383
  • Novo Nordisk$279
  • Pfizer$259
  • AstraZeneca$156
  • Johnson & Johnson$93
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$78
  • plus $421 from 15 others

What the payments were for

  • Food & beverage$1,670100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,670 in reported general payments places this provider in the 85th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$2,920
Medicare patients
32
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$39,068
OzempicSemaglutide19$23,922
MounjaroTirzepatide15$15,662
XareltoRivaroxaban29$13,852
LokelmaSodium Zirconium Cyclosilicate13$10,429
JardianceEmpagliflozin12$7,066
Incruse ElliptaUmeclidinium Bromide13$4,383
Ezetimibe19$1,007
Atorvastatin Calcium75$742
Omeprazole48$589
Potassium Chloride23$523
Carvedilol46$512
Famotidine28$466
Bupropion XlBupropion Hcl17$451
Pantoprazole Sodium33$369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$259$39,06848 claims
Novo NordiskOzempic$279$23,92219 claims
Lilly USA, LLCMounjaro$56$15,66215 claims
Johnson & JohnsonXarelto$93$13,85229 claims
AstraZenecaLokelma$156$10,42913 claims
GSKIncruse Ellipta$52$4,38313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Perrysburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →